NASDAQ:SLGL - Sol Gel Technologies Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $7.00 -0.38 (-5.15 %) (As of 09/21/2018 04:00 PM ET)Previous Close$7.38Today's Range$6.86 - $7.3452-Week Range$6.03 - $16.48Volume10,359 shsAverage Volume52,977 shsMarket Capitalization$134.92 millionP/E Ratio-1.39Dividend YieldN/ABetaN/A Company ProfileDiscussionAnalyst RatingsChartEarnings HistoryHeadlinesOptions ChainSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Sol-Gel Technologies Ltd., a clinical-stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company's lead product candidates include TWIN and SIRS-T, which has completed Phase II clinical trials for the treatment of acne vulgaris; and VERED that has completed Phase II clinical trials for the treatment of papulopustular rosacea. It is also involved in the development of generic dermatological drug products. Sol-Gel Technologies Ltd. has collaboration with Perrigo; and Douglas Pharmaceuticals for the development and commercialization of a generic product candidate. The company was founded in 1997 and is headquartered in Ness Ziona, Israel. Receive SLGL News and Ratings via Email Sign-up to receive the latest news and ratings for SLGL and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical SymbolNASDAQ:SLGL CUSIPN/A Webwww.sol-gel.com Phone972-8931-3433 Debt Debt-to-Equity RatioN/A Current Ratio20.81 Quick Ratio20.81 Price-To-Earnings Trailing P/E Ratio-1.39 Forward P/E Ratio-3.55 P/E GrowthN/A Sales & Book Value Annual Sales$170,000.00 Price / Sales779.06 Cash FlowN/A Price / CashN/A Book ValueN/A Price / BookN/A Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/A Miscellaneous Employees49 Outstanding Shares18,920,000Market Cap$134.92 million Sol Gel Technologies (NASDAQ:SLGL) Frequently Asked Questions What is Sol Gel Technologies' stock symbol? Sol Gel Technologies trades on the NASDAQ under the ticker symbol "SLGL." How were Sol Gel Technologies' earnings last quarter? Sol Gel Technologies Ltd (NASDAQ:SLGL) announced its quarterly earnings results on Wednesday, August, 8th. The company reported ($0.36) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.48) by $0.12. The business earned $0.05 million during the quarter, compared to the consensus estimate of $0.05 million. View Sol Gel Technologies' Earnings History. When is Sol Gel Technologies' next earnings date? Sol Gel Technologies is scheduled to release their next quarterly earnings announcement on Wednesday, November, 14th 2018. View Earnings Estimates for Sol Gel Technologies. What price target have analysts set for SLGL? 4 Wall Street analysts have issued 12 month price objectives for Sol Gel Technologies' stock. Their predictions range from $17.00 to $21.00. On average, they anticipate Sol Gel Technologies' share price to reach $19.00 in the next twelve months. This suggests a possible upside of 171.4% from the stock's current price. View Analyst Price Targets for Sol Gel Technologies. What is the consensus analysts' recommendation for Sol Gel Technologies? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sol Gel Technologies in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Sol Gel Technologies. What are Wall Street analysts saying about Sol Gel Technologies stock? Here are some recent quotes from research analysts about Sol Gel Technologies stock: 1. According to Zacks Investment Research, "Sol-Gel Technologies Ltd.is a clinical-stage dermatology company. It focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. Its product candidates include VERED for the treatment of papulopustular rosacea, TWIN and SIRS-T for the treatment of acne vulgaris, which are in its clinical stage. Sol-Gel Technologies Ltd.is based in Israel. " (7/18/2018) 2. HC Wainwright analysts commented, "Valuation methodology, risks and uncertainties. We have valued Sol-Gel based on a composite assessment of the company’s most advanced clinical-stage drugs. Underlying this, we employ a discounted cash flow (DCF)-based analysis that culminates in a risk-adjusted net present value (rNPV) valuation for each of these agents. This yields a value of $102M for TWIN, assuming a 50% probability of success, and a $323M valuation for VERED, assuming a 60% probability of success. The generic ivermectin cream program contributes a value of $7M to our composite assessment." (7/16/2018) Who are some of Sol Gel Technologies' key competitors? Some companies that are related to Sol Gel Technologies include Theratechnologies (THERF), Prothena (PRTA), ArQule (ARQL), GTX (GTXI), Odonate Therapeutics (ODT), Arbutus Biopharma (ABUS), Adamas Pharmaceuticals (ADMS), Five Prime Therapeutics (FPRX), Aduro BioTech (ADRO), Evolus (EOLS), Aurinia Pharmaceuticals (AUPH), Collegium Pharmaceutical (COLL), Zymeworks (ZYME), Progenics Pharmaceuticals (PGNX) and Aclaris Therapeutics (ACRS). Who are Sol Gel Technologies' key executives? Sol Gel Technologies' management team includes the folowing people: Dr. Alon Seri-Levy, Co-Founder & CEO (Age 57)Prof. David Avnir, Co-FounderMr. Gilad Mamlok, Chief Financial Officer (Age 50)Mr. Itzik Yosef, VP of Operations (Age 42)Ms. Karine Neimann, VP of Projects & Planning and Chief Chemist (Age 47) When did Sol Gel Technologies IPO? (SLGL) raised $60 million in an IPO on Thursday, February 1st 2018. The company issued 5,000,000 shares at $11.00-$13.00 per share. Jefferies and BMO Capital Markets acted as the underwriters for the IPO and JMP Securities and Raymond James were co-managers. When did Sol Gel Technologies' lock-up period expire? Sol Gel Technologies' lock-up period expired on Tuesday, July 31st. Sol Gel Technologies had issued 6,250,000 shares in its initial public offering on February 1st. The total size of the offering was $75,000,000 based on an initial share price of $12.00. Shares of the company owned by major shareholders and company insiders are now eligible to be traded as a result of the end of the lock-up period. Has Sol Gel Technologies been receiving favorable news coverage? Headlines about SLGL stock have trended somewhat positive on Friday, Accern reports. The research group identifies positive and negative news coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Sol Gel Technologies earned a daily sentiment score of 0.18 on Accern's scale. They also assigned headlines about the company an impact score of 46.57 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the near term. View Recent Headlines for Sol Gel Technologies. Who are Sol Gel Technologies' major shareholders? Sol Gel Technologies' stock is owned by many different of institutional and retail investors. Top institutional investors include Delek Group Ltd. (6.71%), Alpine Global Management LLC (0.08%) and Raymond James & Associates (0.07%). Which institutional investors are buying Sol Gel Technologies stock? SLGL stock was bought by a variety of institutional investors in the last quarter, including Delek Group Ltd., Alpine Global Management LLC and Raymond James & Associates. How do I buy shares of Sol Gel Technologies? Shares of SLGL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Sol Gel Technologies' stock price today? One share of SLGL stock can currently be purchased for approximately $7.00. How big of a company is Sol Gel Technologies? Sol Gel Technologies has a market capitalization of $134.92 million and generates $170,000.00 in revenue each year. The company earns $-31,560,000.00 in net income (profit) each year or ($5.02) on an earnings per share basis. Sol Gel Technologies employs 49 workers across the globe. How can I contact Sol Gel Technologies? Sol Gel Technologies' mailing address is 7 GOLDA MEIR ST.WEIZMANN SCIENCE PARK, NESS ZIONA L3, 7403650. The company can be reached via phone at 972-8931-3433. MarketBeat Community Rating for Sol Gel Technologies (NASDAQ SLGL)Community Ranking: 2.4 out of 5 ( )Outperform Votes: 48 (Vote Outperform)Underperform Votes: 53 (Vote Underperform)Total Votes: 101MarketBeat's community ratings are surveys of what our community members think about Sol Gel Technologies and other stocks. Vote "Outperform" if you believe SLGL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SLGL will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 9/21/2018 by MarketBeat.com StaffFeatured Article: What is a Fiduciary?